Anixa Biosciences’ IND for ovarian cancer CAR-T therapy approved by FDA

Anixa Biosciences’ collaborator, Moffitt Cancer Center, has received approval by the FDA of an individual patient Investigational New Drug Application – IND – to allow a second dose of its CAR-T therapy for a patient that may be demonstrating clinical activity to the initial treatment. The Phase I clinical trial at Moffitt is treating recurrent ovarian cancer patients who have failed standard-of-care therapies. To date, six patients have been treated in the dose escalation trial, three in the first cohort and three in the second cohort. Dose escalation will continue after confirming the previous dosages are safe.